CoChat

Lighting Up the Fire in the Microenvironment of Cold Tumors: A Major Challenge to Improve Cancer Immunotherapy

Open access

The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.

Abstract

Immunotherapy includes immune checkpoint inhibitors (ICI) such as antibodies targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or the programmed cell death protein/programmed death ligand 1 (PD-1/PD-L1) axis. Experimental and clinical evidence show that immunotherapy based on immune checkpoint inhibitors (ICI) provides long-term survival benefits to cancer patients in whom other conventional therapies have failed. However, only a minority of patients show high clinical benefits via the use of ICI alone. One of the major factors limiting the clinical benefits to ICI can be attributed to the lack of immune cell infiltration within the tumor microenvironment. Such tumors are classified as "cold/warm" or an immune "desert"; those displaying significant infiltration are considered "hot" or inflamed. This review will provide a brief summary of different tumor properties contributing to the establishment of cold tumors and describe major strategies that could reprogram non-inflamed cold tumors into inflamed hot tumors. More particularly, we will describe how targeting hypoxia can induce metabolic reprogramming that results in improving and extending the benefit of ICI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells12131787

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The different steps of the cancer-immunity cycle. Briefly, the first step of the cycle consists of releasing antigens from tumor cells (1). These antigens are captured by dendritic cells on MHC-I and MHC-II molecules (2) and presented to T cells (3). This step results in T cell priming and activation in lymph nodes. Activated T cells migrate through the blood vessels to infiltrate the tumor microenvironment (4). Defects in several steps in the cancer-immunity cycle results in the establishment of cold tumors (reported in red).
Figure 1 The different steps of the cancer-immunity cycle. Briefly, the first step of the cycle consists of releasing antigens from tumor cells (1). These antigens are captured by dendritic cells on MHC-I and MHC-II molecules (2) and presented to T cells (3). This step results in T cell priming and activation in lymph nodes. Activated T cells migrate through the blood vessels to infiltrate the tumor microenvironment (4). Defects in several steps in the cancer-immunity cycle results in the establishment of cold tumors (reported in red).CC BY · PubMed Central
Figure 2 Summary of the different strategies involved in switching cold into hot tumors and their mode of action. Combining these strategies with immunotherapy improves the therapeutic benefit in cancer patients.
Figure 2 Summary of the different strategies involved in switching cold into hot tumors and their mode of action. Combining these strategies with immunotherapy improves the therapeutic benefit in cancer patients.CC BY · PubMed Central
Figure 3 Summary of the mechanisms involved in HIF-1α regulation in normoxia and hypoxia.
Figure 3 Summary of the mechanisms involved in HIF-1α regulation in normoxia and hypoxia.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 149 references

Cited by

See all 39

Metadata

Authors
Benoit, A., Vogin, G., Duhem, C., Berchem, G., & Janji, B.
Affiliations
  • Luxembourg Institute of Health (LU)
  • Centre François Baclesse (LU)
  • Centre Hospitalier de Luxembourg (LU)
Corresponding author
Janji, Bassam
Venue
Cells
Publisher
MDPI AG
Published
2023-07-05
Volume
12
Issue
13
Pages
1787
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4383375914
Cited by
39
References
149
Citations by year
2026: 9 · 2025: 14 · 2024: 11 · 2023: 5
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • FNRS Televie (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
  • Roche Pharma 2023 (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
  • RCMS foundation (INCOM BIOM) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
  • Luxembourg National Research Fund (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
  • Kriibskrank Kanner Foundation, Luxembourg (2019) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
  • Action LIONS Vaincre le Cancer Luxembourg (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
  • Stiftelsen Cancera (CombiN 2023) (7.4559.21 IMPACT21, 7.4560.21 INCITE21, BRIDGES2020/BM/15412275/SMART-COMBO, BRIDGES2021/BM/16358198/TRICK-ALDH, INTER/EUROSTARS21/16896480/C2I, INTER/EUROSTARS21/16896735/PreCyse)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
cold tumors, tumor microenvironment, cancer immunotherapy, immune checkpoint inhibitors, CTLA-4, PD-1/PD-L1 axis, tumor immune infiltration, tumor hypoxia, metabolic reprogramming, tumor reprogramming
MeSH terms
Immune Checkpoint Inhibitors, Humans, Immunotherapy, Neoplasms, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.